Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927237 | 0.92 | KDM1A (0.39) | KDM1ACYP3A4CYP1A2MAPK1CYP2D6 | |
| SCHEMBL4926841 | 0.91 | KDM1A (0.50) | KDM1AMGLLCHRNA7 | |
| SCHEMBL4925062 | 0.89 | KDM1A (0.46) | KDM1A | |
| SCHEMBL4930129 | 0.88 | KDM1A (0.48) | KDM1AMGLL | |
| SCHEMBL14564062 | 0.88 | KDM1A (0.45) | KDM1ACYP3A4CYP1A2MAPK1MGLL | |
| SCHEMBL4931192 | 0.88 | MGLL (0.45) | KDM1ACYP3A4CYP1A2MAPK1CYP2C9 | |
| SCHEMBL5266989 | 0.88 | KDM1A (0.51) | KDM1ACHRNA7 | |
| SCHEMBL4932719 | 0.87 | MGLL (0.49) | KDM1ACYP3A4ALDH1A1MGLL | |
| SCHEMBL4931684 | 0.87 | KDM1A (0.43) | KDM1ACYP3A4CYP2C9MGLLCHRNA7 | |
| SCHEMBL4927988 | 0.87 | MGLL (0.49) | KDM1AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | KDM1A 559/4885CYP3A4 65/4885CYP1A2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.